Colchicine 0.5 MG Oral Tablet Once Daily

DRUG3 trials

Sponsors

Dongying Zhang, Shanghai Tongji Hospital, Tongji University School of Medicine, Duke University

Conditions

ACS - Acute Coronary SyndromeChronic InflammationColchicineCoronary Artery Disease ProgressionCoronary Artery Disease Risk Factors MultipleHeart FailureHeart Failure with Preserved Ejection Fraction (HFPEF)Inflammation

Phase 3

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

Not yet recruitingNCT07232069

Duke UniversityCoronary Artery Disease Progression, Coronary Artery Disease Risk Factors Multiple, Premature Atherosclerosis +1

Start: 2026-07-01End: 2031-07-01Target: 1500Updated: 2026-02-27

Phase 4

Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation

Not yet recruitingNCT06604611

Dongying ZhangChronic Inflammation, Colchicine, Heart Failure +2

Start: 2024-10-31End: 2026-03-31Target: 200Updated: 2024-09-19

Unknown Phase

Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients

RecruitingNCT07064109

Shanghai Tongji Hospital, Tongji University School of MedicineACS - Acute Coronary Syndrome

Start: 2025-07-01End: 2027-07-01Target: 380Updated: 2025-09-15